The market for peptide drugs in the United States is rapidly shifting to cryptocurrency payments. In the first quarter of 2026, sellers of such products received $32 million in digital assets from buyers, a 700% increase compared to the same period last year. Chainalysis analysts are recording explosive growth in this segment, which was previously niche.

Peptides, marketed as weight loss, muscle building, and anti-aging products, are increasingly being sold outside the traditional pharmacy network. Approved drugs, such as Eli Lilly's retatrutide, can be purchased at Walgreens or CVS, but a significant share of online trade is moving into the gray zone. Cheap analogs are imported from foreign laboratories without a prescription or insurance, and packaging often bears the label "not for human use."

Why cryptocurrency became the standard

Banks and payment systems refuse to service such sellers due to high compliance risks. As a result, many suppliers only accept payment in bitcoin. For some buyers, this becomes their first experience using cryptocurrency. For example, 49-year-old marketing director Zack from the northwestern United States, looking for retatrutide, found a Chinese supplier who agreed to ship 20 vials for $240. On the American market, such a purchase would have cost him $300 per month. The seller only accepted digital assets, and Zack had to buy bitcoin for the first time in his life.

Three stages of growth

Chainalysis identifies three key stages in the market's development. Until 2025, it was an underground market with a monthly inflow of about $200,000. Then the topic came to the attention of the Make America Healthy Again movement, and growth coincided with the appointment of Robert F. Kennedy Jr. as head of the U.S. Department of Health and Human Services. Establishing a direct causal relationship from on-chain data is difficult, but the correlation is obvious.

A sharp surge occurred in late 2025 after the topic entered the TikTok subculture looksmaxxing, whose followers are obsessed with improving their appearance. The average monthly inflow quadrupled to $9.9 million, and in peak months exceeded $10 million. For comparison, according to estimates by former Coinbase employee Sarah Graham, the annual turnover of the peptide market in 2023 was about $100 million. TRM Labs data for 2025 shows inflows of $41.4 million — a 20% increase year-over-year. TRM Labs' Global Director of Policy Ari Redbond compares this dynamic to the early stages of shadow online markets like Silk Road.

Major players are moving to stablecoins

The market is unevenly structured. The bulk of the volume comes from a narrow group of large sellers with a broad client base. Small players experiment with different coins, but large suppliers almost exclusively use bitcoin and stablecoins. Sellers with an average deposit of $1,000 or more predominantly use "stablecoins" — this hedges against volatility in large and cross-border purchases.

The Chinese connection

The main raw materials for peptides are produced in China. Chinese chemical companies are actively expanding their presence in this niche. Over the three quarters of last year, imports from China to the U.S. doubled, exceeding $300 million. Some suppliers have switched to peptides from the drug business. For example, Chinese company Bigreat Technology, which previously supplied fentanyl and amphetamine precursors to Russia and Kazakhstan, created a separate legal entity, Zhengzhou DEPU Technology, to sell cosmetic peptides.

My analysis: This case clearly demonstrates how cryptocurrency is becoming a payment tool for markets where traditional finance is powerless. A 700% growth in a year is not just statistics, but a signal of the formation of a new shadow segment that could influence regulatory approaches to stablecoins and bitcoin. Investors should closely monitor this dynamic: it could set a precedent for other gray markets.